
    
      PROTOCOL OUTLINE: Only 2 patients with tyrosinemia type I are known to this research team;
      others will be treated if found and if clinical conditions permit.

      The enzyme inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is
      administered orally, in 2 divided doses daily with meals.

      Patients will be followed closely for side effects attributable to NTBC.
    
  